[go: up one dir, main page]

CN110709409A - 一种甾族类衍生物调节剂及其制备方法和应用 - Google Patents

一种甾族类衍生物调节剂及其制备方法和应用 Download PDF

Info

Publication number
CN110709409A
CN110709409A CN201980001355.3A CN201980001355A CN110709409A CN 110709409 A CN110709409 A CN 110709409A CN 201980001355 A CN201980001355 A CN 201980001355A CN 110709409 A CN110709409 A CN 110709409A
Authority
CN
China
Prior art keywords
cyclopenta
hydroxy
phenanthren
group
ethan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980001355.3A
Other languages
English (en)
Other versions
CN110709409B (zh
Inventor
苏熠东
邓海宁
陈晓坡
包如迪
张福军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority to CN202210400900.XA priority Critical patent/CN114656514B/zh
Priority to CN202210401606.0A priority patent/CN114805462B/zh
Publication of CN110709409A publication Critical patent/CN110709409A/zh
Application granted granted Critical
Publication of CN110709409B publication Critical patent/CN110709409B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/0025—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明涉及一种甾族类衍生物调节剂及其制备方法和应用。特别地，本发明涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为GABAA受体调节剂在治疗抑郁症、惊厥、帕金森和神经系统疾病的用途，其中通式(I)中的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201980001355.3A 2018-02-11 2019-01-31 一种甾族类衍生物调节剂及其制备方法和应用 Active CN110709409B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210400900.XA CN114656514B (zh) 2018-02-11 2019-01-31 一种甾族类衍生物调节剂及其制备方法和应用
CN202210401606.0A CN114805462B (zh) 2018-02-11 2019-01-31 一种甾族类衍生物调节剂及其制备方法和应用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN201810141153 2018-02-11
CN2018101411536 2018-02-11
CN201810180543 2018-03-05
CN2018101805434 2018-03-05
CN201810491114 2018-05-21
CN2018104911149 2018-05-21
CN2018107719644 2018-07-13
CN201810771964 2018-07-13
CN2018114080813 2018-11-23
CN201811408081 2018-11-23
PCT/CN2019/074134 WO2019154257A1 (zh) 2018-02-11 2019-01-31 一种甾族类衍生物调节剂及其制备方法和应用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202210401606.0A Division CN114805462B (zh) 2018-02-11 2019-01-31 一种甾族类衍生物调节剂及其制备方法和应用
CN202210400900.XA Division CN114656514B (zh) 2018-02-11 2019-01-31 一种甾族类衍生物调节剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN110709409A true CN110709409A (zh) 2020-01-17
CN110709409B CN110709409B (zh) 2022-05-31

Family

ID=67548159

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980001355.3A Active CN110709409B (zh) 2018-02-11 2019-01-31 一种甾族类衍生物调节剂及其制备方法和应用
CN202210400900.XA Active CN114656514B (zh) 2018-02-11 2019-01-31 一种甾族类衍生物调节剂及其制备方法和应用
CN202210401606.0A Active CN114805462B (zh) 2018-02-11 2019-01-31 一种甾族类衍生物调节剂及其制备方法和应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210400900.XA Active CN114656514B (zh) 2018-02-11 2019-01-31 一种甾族类衍生物调节剂及其制备方法和应用
CN202210401606.0A Active CN114805462B (zh) 2018-02-11 2019-01-31 一种甾族类衍生物调节剂及其制备方法和应用

Country Status (12)

Country Link
US (2) US12139508B2 (zh)
EP (1) EP3750908A4 (zh)
JP (2) JP7438956B2 (zh)
KR (1) KR20200120661A (zh)
CN (3) CN110709409B (zh)
AU (1) AU2019218177B2 (zh)
BR (1) BR112020016269A2 (zh)
CA (1) CA3090724A1 (zh)
MX (1) MX2020008422A (zh)
TW (1) TWI874306B (zh)
WO (1) WO2019154257A1 (zh)
ZA (1) ZA202005151B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638928A (zh) * 2019-08-07 2021-04-09 上海翰森生物医药科技有限公司 一种甾族类衍生物调节剂的盐及其晶型

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
DK3864022T3 (da) 2018-10-12 2023-12-18 Sage Therapeutics Inc Neuroaktive steroider substitueret i Position 10 med en cyklisk gruppe til anvendelse til behandlingen af CNS-lidelser
IL312610A (en) 2018-12-05 2024-07-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
CN113272315B (zh) * 2018-12-26 2023-08-08 张家口华健致远生物科技有限公司 一类类固醇化合物及其用途
CN115651054B (zh) * 2019-01-08 2024-06-21 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
BR112021024033A2 (pt) 2019-05-31 2022-02-08 Sage Therapeutics Inc Esteroides neuroativos e suas composições
CA3143545A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
US20230414636A1 (en) 2020-03-25 2023-12-28 Sage Therapeutics, Inc. Use of gabaa modulators for treatment of respiratory conditions
WO2022115381A1 (en) * 2020-11-25 2022-06-02 Sage Therapeutics, Onc. Compositions and methods for treating cns disorders cross reference to related application
CN113968886B (zh) * 2021-11-15 2022-12-13 湖南科瑞生物制药股份有限公司 一种17-甲酸甾体化合物的制备方法
CN114933624B (zh) * 2022-05-24 2024-02-20 大连理工大学 一种天然产物(+)-毛地黄毒苷配基的人工合成方法

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012510A (en) * 1974-11-11 1977-03-15 Schering Aktiengesellschaft Novel methylene steroids
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
CN1190404A (zh) * 1995-06-06 1998-08-12 科斯赛斯公司 雄甾烷和孕甾烷系列的神经活性甾族化合物
WO2013019711A2 (en) * 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
WO2014169836A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169832A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
CN104136452A (zh) * 2011-10-14 2014-11-05 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
CN105339381A (zh) * 2013-04-17 2016-02-17 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
WO2016061537A1 (en) * 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016084790A1 (ja) * 2014-11-25 2016-06-02 第一三共株式会社 ヒドロナフトキノリン誘導体
CN106661078A (zh) * 2014-05-29 2017-05-10 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
WO2018013615A1 (en) * 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU609927B2 (en) * 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
GB9213835D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Compounds
FR2718138B1 (fr) * 1994-04-01 1996-04-26 Roussel Uclaf Nouveaux stéroïdes comportant en position 20 une chaîne aminosubstituée, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les renfermant.
WO1995028413A1 (en) * 1994-04-15 1995-10-26 Smithkline Beecham Corporation 17β-SUBSTITUTED 3-CARBOXY STEROIDS THAT INHIBIT 5-α-REDUCTASE
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
JP4516316B2 (ja) 2002-03-13 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション アンドロゲン受容体モジュレーターとしてのフッ化４−アザステロイド誘導体
TWI391381B (zh) * 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
RS61370B1 (sr) 2013-08-23 2021-02-26 Sage Therapeutics Inc Neuroaktivni steroidi, njihove kompozicije i upotreba

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012510A (en) * 1974-11-11 1977-03-15 Schering Aktiengesellschaft Novel methylene steroids
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
CN1190404A (zh) * 1995-06-06 1998-08-12 科斯赛斯公司 雄甾烷和孕甾烷系列的神经活性甾族化合物
WO2013019711A2 (en) * 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
US20140148412A1 (en) * 2011-07-29 2014-05-29 The Regents Of The University Of Claifornia Novel 17b-heteroaryl-substituted steroids as modulators of gabaa receptors
CN104136452A (zh) * 2011-10-14 2014-11-05 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
WO2014169832A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) * 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
CN105246909A (zh) * 2013-04-17 2016-01-13 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
CN105339381A (zh) * 2013-04-17 2016-02-17 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
US20170233432A1 (en) * 2013-04-17 2017-08-17 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
CN106661078A (zh) * 2014-05-29 2017-05-10 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
WO2016061537A1 (en) * 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016084790A1 (ja) * 2014-11-25 2016-06-02 第一三共株式会社 ヒドロナフトキノリン誘導体
TW201629015A (zh) * 2014-11-25 2016-08-16 第一三共股份有限公司 氫萘喹啉衍生物
WO2018013615A1 (en) * 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADRIANA S. VELEIRO等: "Synthesisand GABAA Receptor Activity of a 6,19-Oxido Analogue of Pregnanolone", 《BIOORG.MED.CHME.LETT.》 *
ALISON ANDERSON等: "Conformationally constrainedamestjetoc steroids that modulate GABAA receptors", 《J.MED.CHEM.》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638928A (zh) * 2019-08-07 2021-04-09 上海翰森生物医药科技有限公司 一种甾族类衍生物调节剂的盐及其晶型
CN112638928B (zh) * 2019-08-07 2023-12-22 上海翰森生物医药科技有限公司 一种甾族类衍生物调节剂的盐及其晶型

Also Published As

Publication number Publication date
AU2019218177B2 (en) 2024-02-01
US20250051387A1 (en) 2025-02-13
WO2019154257A1 (zh) 2019-08-15
JP2021513532A (ja) 2021-05-27
JP2024045458A (ja) 2024-04-02
EP3750908A4 (en) 2022-07-27
ZA202005151B (en) 2024-12-18
KR20200120661A (ko) 2020-10-21
US20210139530A1 (en) 2021-05-13
BR112020016269A2 (pt) 2020-12-15
TWI874306B (zh) 2025-03-01
CN114805462B (zh) 2024-06-18
JP7438956B2 (ja) 2024-02-27
JP7741907B2 (ja) 2025-09-18
CN110709409B (zh) 2022-05-31
CA3090724A1 (en) 2019-08-15
CN114805462A (zh) 2022-07-29
MX2020008422A (es) 2020-09-21
TW201934125A (zh) 2019-09-01
CN114656514A (zh) 2022-06-24
RU2020126096A (ru) 2022-03-11
EP3750908A1 (en) 2020-12-16
US12139508B2 (en) 2024-11-12
AU2019218177A1 (en) 2020-09-17
CN114656514B (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
CN114805462B (zh) 一种甾族类衍生物调节剂及其制备方法和应用
CN110366555B (zh) 甾族类衍生物调节剂、其制备方法和应用
WO2024022444A1 (zh) 稠环类化合物、其制备方法及其在医药上的应用
CN108623615B (zh) 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
CN103958480B (zh) 咪唑啉类衍生物、其制备方法及其在医药上的应用
WO2022247816A1 (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
KR102847070B1 (ko) 아자비시클릭 치환된 옥사스피로 유도체, 이의 제조 방법 및 의학적 용도
TW202041217A (zh) 一種多環類衍生物調節劑、其製備方法和應用
WO2024094171A1 (zh) 取代的氨基嘧啶类化合物、其制备方法及其在医药上的应用
WO2020192750A1 (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
CN112638928B (zh) 一种甾族类衍生物调节剂的盐及其晶型
HK40013442B (zh) 一种甾族类衍生物调节剂及其制备方法和应用
HK40013442A (zh) 一种甾族类衍生物调节剂及其制备方法和应用
RU2797408C2 (ru) Регуляторы-производные стероидов, способы их получения и их применение
HK40011736A (zh) 甾族类衍生物调节剂、其制备方法和应用
HK40011736B (zh) 甾族类衍生物调节剂、其制备方法和应用
HK40041170A (zh) 一种甾族类衍生物调节剂的盐及其晶型
CN117659023A (zh) 吡啶乙酰胺类衍生物、包含其的药物组合物及其医药用途
TW202345811A (zh) 吲唑類化合物、其製備方法及其在醫藥上的應用
HK40059624A (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013442

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant